A New Standard Treatment for Older Individuals with Hodgkin Lymphoma

For patients aged ≥60 with advanced-stage disease, front-line nivolumab plus AVD chemotherapy yielded better outcomes than brentuximab vedotin plus AVD.

Patients over 60 with classic Hodgkin lymphoma (cHL) have worse treatment responses and outcomes than younger patients due to comorbidities, poor tolerance of therapy, and differences in HL biology. In the S1826 study, investigators assessed 6 cycles of the immune checkpoint inhibitor nivolumab (N) plus AVD (doxorubicin, vinblastine, and dacarbazine) versus brentuximab vedotin (BV) plus AVD in previously untreated patients with advanced-stage cHL and stratified by age group.

Key findings for participants aged ≥60 years:

Two-year progression-free survival was significantly better for N-AVD (89%) than BV-AVD (64%); 2-year overall survival was 96% vs. 85%.
Adverse events (including peripheral neuropathy) were more common with BV-AVD, and dose red…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

A New Standard Treatment for Older Individuals with Hodgkin Lymphoma

Topics

Reviewing Author